Carroll Investors’s AstraZeneca AZN Stock Holding History

Carroll Investors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-285	Closed	-$37K	–	42
2022 Q1	$37K	Hold	285	–	–	0.02%	91
2021 Q4	$33K	Buy	+285	New	+$33.5K	0.02%	114

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Carroll Investors's AZN Position: Q2 2022 in Review

Carroll Investors sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 285 shares — an estimated $37K sold.

Carroll Investors first reported a position in AZN in Q4 2021 and held it in 2 quarters. The position peaked at $37K in Q1 2022. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Carroll Investors reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
Carroll Investors sold 285 AstraZeneca shares in Q2 2022, an estimated $37K.
Carroll Investors first reported a position in AstraZeneca in Q4 2021 and held it in 2 quarters.
Carroll Investors's AstraZeneca position peaked at $37K in Q1 2022.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Carroll Investors's 13F filing for Q2 2022, filed 26 Jul 2022.